TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Childhood Obesity Prevention Program: Building Better Families and Communities
Brief Summary: This study is proposed on behalf of the Hartford Childhood Wellness Alliance, a 107 member, 35 group organization whose goal is to improve the health of children in Hartford, CT. In a randomized control trial, the primary aim of this study is to test the initial efficacy of a program of enhanced home visitation with neighborhood and community support to change maternal behaviors related to infant nutrition (sweetened beverage/juice consumption, breastfeeding and introduction of solids), parenting skills (establishing routines around sleep, reading cues for hunger, satiety, television time) and family wellness (improving the home food environment, enhancing physical activity). The investigators hypothesize that at 12 months of age, infants in the intervention arm will drink less sugar sweetened beverages/juices, will have ingested solids at an older age, will have been breastfed longer and more exclusively than infants in the control arm and will have less TV viewing, more established sleep routines and greater soothability (primary outcomes).


Options:
A: Arm Label: Enhanced NFN Home Program; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Arm Label: Nurturing Family Network Home Visitation; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Experimental | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): Enhanced NFN Home Program, Nurturing Family Network Home Visitation
B: Arm Label: Tools for Teen Moms Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tools for Teen Moms | Arm Label: MIHP standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tools for Teen Moms; Assigned to Arm(s): Tools for Teen Moms Intervention Group
C: Arm Label: Program participation; Type: EXPERIMENTAL; Interventions: Other: Enhanced-Homestead Food Production Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced-Homestead Food Production Program; Assigned to Arm(s): Program participation
D: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older
Brief Summary: The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.


Options:
A: Arm Label: SC HZ/su Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: IM HZ/su Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): IM HZ/su Group, SC HZ/su Group
B: Arm Label: Concomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Arm Label: Nonconcomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Placebo to ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Influenza Vaccine; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination
C: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Boostrix | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Control Group, GSK1437173A Group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Control Group, GSK1437173A Group
D: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Assigned to Arm(s): Co-Ad Group, Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adventitious Lung Sounds as Indicators of Severity and Recovery of Lung Pathology and Sputum Location
Brief Summary: This study aims to assess the responsiveness to change of adventitious lung sounds (ALS) in patients with lower respiratory tract infection (LRTI).

Patients will be recruited from a central Hospital and their demographic and anthropometric data, lung sounds, lung function, breathlessness, oxygen saturation and chest HRCT scan will be collected within 24h of the first appointment. Then, patients will be randomly allocated to either conventional treatment or conventional treatment plus respiratory physiotherapy. Conventional treatment will consist on daily medical treatment prescribed by the physician. Respiratory physiotherapy will involve 9 sessions (3 times a week during 2 weeks) of breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.

It is expected that ALS will be responsive to changes in patients' lung function after treatment. It is also expected that, by including a respiratory physiotherapy component in the treatment of patients with LRTI, they will express more improvements in a shorter period of time.


Options:
A: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment
B: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging
C: Arm Label: Mindfulness Meditation; Type: EXPERIMENTAL; Interventions: Other: Mindfulness Meditation | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mindfulness Meditation; Assigned to Arm(s): Mindfulness Meditation | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Waiting list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Meditation | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adventitious Lung Sounds as Indicators of Severity and Recovery of Lung Pathology and Sputum Location
Brief Summary: This study aims to assess the responsiveness to change of adventitious lung sounds (ALS) in patients with lower respiratory tract infection (LRTI).

Patients will be recruited from a central Hospital and their demographic and anthropometric data, lung sounds, lung function, breathlessness, oxygen saturation and chest HRCT scan will be collected within 24h of the first appointment. Then, patients will be randomly allocated to either conventional treatment or conventional treatment plus respiratory physiotherapy. Conventional treatment will consist on daily medical treatment prescribed by the physician. Respiratory physiotherapy will involve 9 sessions (3 times a week during 2 weeks) of breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.

It is expected that ALS will be responsive to changes in patients' lung function after treatment. It is also expected that, by including a respiratory physiotherapy component in the treatment of patients with LRTI, they will express more improvements in a shorter period of time.


Options:
A: Intervention Type: OTHER; Name: other; Assigned to Arm(s): N/A
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy program | Arm Label: Control group; Type: OTHER; Interventions: Drug: cephalosporin with or without erythromycin | Intervention Type: DRUG; Name: cephalosporin with or without erythromycin; Assigned to Arm(s): Control group | Intervention Type: OTHER; Name: Physiotherapy program; Assigned to Arm(s): Experimental group
C: Arm Label: Osteopathic Manipulative Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Osteopathic Manipulative Treatment | Arm Label: Light-touch Treatment; Type: SHAM_COMPARATOR; Interventions: Procedure: Light-touch Treatment | Arm Label: Conventional Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Osteopathic Manipulative Treatment; Assigned to Arm(s): Osteopathic Manipulative Treatment | Intervention Type: PROCEDURE; Name: Light-touch Treatment; Assigned to Arm(s): Light-touch Treatment
D: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section
Brief Summary: The use of Oxytocin, Carbetocin and buccal misoprostol in patients undergoing elective Cesarean Section


Options:
A: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
B: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
C: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
D: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section
Brief Summary: The use of Oxytocin, Carbetocin and buccal misoprostol in patients undergoing elective Cesarean Section


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
B: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
C: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Brief Summary: The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture. Specimens of blood and sputum or throat swabs will be taken during the study along with pulmonary function testing. Participants will receive initial treatment with TIS followed additional treatment with TIS if quarterly respiratory cultures are positive for Pa in addition to either azithromycin or placebo for 18 months.


Options:
A: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
B: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
C: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
D: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Brief Summary: The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture. Specimens of blood and sputum or throat swabs will be taken during the study along with pulmonary function testing. Participants will receive initial treatment with TIS followed additional treatment with TIS if quarterly respiratory cultures are positive for Pa in addition to either azithromycin or placebo for 18 months.


Options:
A: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
B: Arm Label: Arikayce™; Type: EXPERIMENTAL; Interventions: Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Arm Label: TOBI®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Intervention Type: DRUG; Name: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.; Assigned to Arm(s): Arikayce™ | Intervention Type: DRUG; Name: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.; Assigned to Arm(s): TOBI®
C: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Brief Summary: The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture. Specimens of blood and sputum or throat swabs will be taken during the study along with pulmonary function testing. Participants will receive initial treatment with TIS followed additional treatment with TIS if quarterly respiratory cultures are positive for Pa in addition to either azithromycin or placebo for 18 months.


Options:
A: Arm Label: azithromycin liquid preparation; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: inert liquid preparation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo control | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): azithromycin liquid preparation | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): inert liquid preparation
B: Arm Label: AZLI 75 mg 3 times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: Aztreonam for Inhalation Solution (AZLI) | Arm Label: TIS 300 mg 2 times a day (BID); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Solution (TIS) | Intervention Type: DRUG; Name: Aztreonam for Inhalation Solution (AZLI); Assigned to Arm(s): AZLI 75 mg 3 times a day (TID) | Intervention Type: DRUG; Name: Tobramycin Inhalation Solution (TIS); Assigned to Arm(s): TIS 300 mg 2 times a day (BID)
C: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin 250 mg tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: azithromycin 250 mg tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): Placebo

Answer: C